1009646-54-1

Basic information

• Product Name: {4-[6-[(3,5-dimethylphenylamino)methyl]-1-(3-hydroxy-6-methylpyridin-2-ylmethyl)-1H-benzoimidazol-2-ylamino]piperidin-1-yl}acetic acid ethyl ester
• Synonyms: {4-[6-[(3,5-dimethylphenylamino)methyl]-1-(3-hydroxy-6-methylpyridin-2-ylmethyl)-1H-benzoimidazol-2-ylamino]piperidin-1-yl}acetic acid ethyl ester
• CAS NO: 1009646-54-1
• Molecular Weight: 556.708
• Mol File: 1009646-54-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: {4-[6-[(3,5-dimethylphenylamino)methyl]-1-(3-hydroxy-6-methylpyridin-2-ylmethyl)-1H-benzoimidazol-2-ylamino]piperidin-1-yl}acetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: {4-[6-[(3,5-dimethylphenylamino)methyl]-1-(3-hydroxy-6-methylpyridin-2-ylmethyl)-1H-benzoimidazol-2-ylamino]piperidin-1-yl}acetic acid ethyl ester(1009646-54-1)
• EPA Substance Registry System: {4-[6-[(3,5-dimethylphenylamino)methyl]-1-(3-hydroxy-6-methylpyridin-2-ylmethyl)-1H-benzoimidazol-2-ylamino]piperidin-1-yl}acetic acid ethyl ester(1009646-54-1)

Safety Data

• Hazardous Substances Data: 1009646-54-1(Hazardous Substances Data)

Upstream product

• 1009646-49-4 {4-[6-formyl-1-(3-hydroxy-6-methylpyridin-2-ylmethyl)-1H-benzoimidazol-2-ylamino]piperidin-1-yl}acetic acid ethyl ester 
• 108-69-0 3,5-dimethylaminoaniline 

Relevant articles and documents

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)

A preceding paper (Bonfanti et al. J. Med Chem. 2007, 50, 4572-4584) reported the optimization of the pharmacokinetic profile of substituted benzimidazoles by reducing their tissue retention. However, the modifications that were necessary to achieve this goal also led to a significant drop in anti-RSV activity. This paper describes a molecular modeling study followed by a lead optimization program that led to the recovery of the initial potent antiviral activity and the selection of TMC353121 as a clinical candidate.